HIV-1 associated dementia: Update on pathological mechanisms and therapeutic approaches

Current Opinion in Neurology

Volumn 22, Issue 3, 2009, Pages 315-320

  Kaul, Marcus ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

Dementia; HIV AIDS; Neurogenesis; Neurotoxicity; Therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIOXIDANT; ANTIRETROVIRUS AGENT; CITALOPRAM; ERYTHROPOIETIN; LITHIUM; MARAVIROC; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROTROPHIN; PAROXETINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SOMATOMEDIN; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; COGNITION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DISEASE ASSOCIATION; DISEASE MARKER; DRUG INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NEUROPATHOLOGY; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; HIV-1; HUMANS;

EID: 67049171319     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328329cf3c     Document Type: Review

References (51)

1. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69:1789-1799. The latest nomenclature and definitions for HAND and HAD.
2. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 1993; 43:2245-2252.
3. Ellis RJ, Deutsch R, Heaton RK, et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobe-havioral Research Center Group. Arch Neurol 1997; 54:416-424.
4. Liner li KJ, Hall CD, Robertson KR. Effects of antiretroviral therapy on cognitive impairment. Curr HIV/AIDS Rep 2008; 5:64-71. Concise and very informative review on the impact of cART/HAART on HAND.
5. Boisse L, Gill MJ, Power C. HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin 2008; 26:799-819. Concise, up-to-date review of HIV-induced neurological diseases.
6. Brew BJ, Crowe SM, Landay A, et al. Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol 2008 [Epub ahead of print]. Informative review and discussion of potential links between HAND, development of HAD, and other neurodegenerative diseases and aging.
7. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70. This study provides a reality-check of the CNS penetration-effectiveness rank.
8. Anthony IC, Bell JE. The neuropathology of HIV/AIDS. Int Rev Psychiatry 2008; 20:15-24. Informative discussion of HIV neuropathology in the eras preintroduction and postintroduction of HAART.
9. Masliah E, Heaton RK, Marcotte TD, et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC group. The HIV Neurobehavioral Research Center. Ann Neurol 1997; 42:963-972.
10. Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 1995; 38:755-762.
11. Esiri MM, Biddolph SC, Morris CS. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry 1998; 65:29-33.
12. Khanlou N, Moore DJ, Chana G, et al. Increased frequency of alpha-synuclein in the substantia nigra in human immunodeficiency virus infection. J Neurovirol 2008 [Epub ahead of print]. This study reports the occurrence of Parkinson's disease-like neuropathology in brains of HAND/HAD patients.
13. Chang L, Wong V, Nakama H, et al. Greater than age-related changes in brain diffusion of HIV patients after 1 year. J Neuroimmune Pharmacol 2008; 3:265-274. This study provides valuable insights into the question of how HIV infection may be linked to age-related changes in the brain.
14. Alirezaei M, Kiosses WB, Flynn CT, et al. Disruption of neuronal autophagy by infected microglia results in neurodegeneration. PLoS ONE 2008; 3:e2906. First report linking HAD to inhibition of autophagy.
15. Li W, Malpica-Llanos TM, Gundry R, et al. Nitrosative stress with HIV dementia causes decreased L-prostaglandin D synthase activity. Neurology 2008; 70:1753-1762.
16. Huang JS, Letendre S, Marquie-Beck J, et al. Low CSF leptin levels are associated with worse learning and memory performance in HIV-infected men. J Neuroimmune Pharmacol 2007; 2:352-358.
17. Burdo TH, Ellis RJ, Fox HS. Osteopontin is increased in HIV-associated dementia. J Infect Dis 2008; 198:715-722. This study suggested osteopontin as a biomarker for HAD.
18. Marcondes MC, Lanigan CM, Burdo TH, et al. Increased expression of monocyte CD44v6 correlates with the development of encephalitis in rhesus macaques infected with simian immunodeficiency virus. J Infect Dis 2008; 197:1567-1576. This study found in an SIV model that increased expression of CD44v6, the osteopontin receptor, on peripheral monocytes predicted SIVE.
19. Wikoff WR, Pendyala G, Siuzdak G, Fox HS. Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. J Clin Invest 2008; 118:2661-2669.
20. Lentz MR, Lee V, Westmoreland SV, et al. Factor analysis reveals differences in brain metabolism in macaques with SIV/AIDS and those with SIV-induced encephalitis. NMR Biomed 2008; 21:878-887. This study used a novel approach to MRS data analysis and detected two metabolite patterns that discerned SIVE from SIV/AIDS.
21. Sailasuta N, Shriner K, Ross B. Evidence of reduced glutamate in the frontal lobe of HIV-seropositive patients(dagger). NMR Biomed 2008; 22:326-331.
22. Ances BM, Roc AC, Korczykowski M, et al. Combination antiretroviral therapy modulates the blood oxygen level-dependent amplitude in human immunodeficiency virus-seropositive patients. J Neurovirol 2008; 14:418-424.
23. Giulian D, Vaca K, Noonan CA. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science 1990; 250:1593-1596.
24. Krathwohl MD, Kaiser JL. HIV-1 promotes quiescence in human neural progenitor cells. J Infect Dis 2004; 190:216-226.
25. Okamoto S, Kang Y, Breohtel C, et al. HIV/gp120 decreases adult neural progenitor cell proliferation via checkpoint kinase-mediated cell cycle withdrawal and G1 arrest. Cell Stem Cell 2007; 1:230-236. This study provides a molecular mechanism for inhibition of neurogenesis by HIV/gp120.
26. Kaul M, Ma Q, Medders KE, et al. HIV-1 coreceptors CCR5 and CXCR4 both mediate neuronal cell death but CCR5 paradoxically can also contribute to protection. Cell Death Differ 2007; 14:296-305.
27. Kaul M. HIV's double strike at the brain: neuronal toxicity and compromised neurogenesis. Front Biosci 2008; 13:2484-2494.
28. Mandl JN, Barry AP, Vanderford TH, et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med 2008; 14:1077-1087. This study provides a potential explanation of how HIV infection leads to pathologic immune suppression and AIDS.
29. Sas AR, Bimonte-Nelson HA, Tyor WR. Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of interferon-alpha in the brain. AIDS 2007; 21:2151-2159.
30. Dudaronek JM, Barber SA, Clements JE. CUGBP1 is required for IFNbeta-mediated induction of dominant-negative CEBPbeta and suppression of SIV replication in macrophages. J Immunol 2007; 179:7262-7269.
31. Kitai R, Zhao ML, Zhang N, et al. Role of MIP-1 beta and RANTES in HIV-1 infection of microglia: inhibition of infection and induction by IFNbeta. J Neuroimmunol 2000; 110:230-239.
32. Garzino-Demo A, Devico AL, Cocchi F, Gallo RC. Beta-chemokines and protection from HIV type 1 disease. AIDS Res Hum Retroviruses 1998; 14 (Suppl 2):S177-S184.
33. + monocytes, MΦ and microglia in the development of SIVE/HIVE and HAD.
34. Samah B, Porcheray F, Dereuddre-Bosquet N, Gras G. Nerve growth factor stimulation promotes CXCL-12 attraction of monocytes but decreases human immunodeficiency virus replication in attracted population. J Neurovirol 2008; 15:71-80.
35. Douglas SD, Lai JP, Tuluc F, et al. Neurokinin-1 receptor expression and function in human macrophages and brain: perspective on the role in HIV neuropathogenesis. Ann N Y Acad Sci 2008; 1144:90-96.
36. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS ONE 2008; 3:e2516. This study suggested that elevated peripheral LPS levels promote the development of HAD.
37. Wang H, Sun J, Goldstein H. Human immunodeficiency virus type 1 infection increases the in vivo capacity of peripheral monocytes to cross the blood-brain barrier into the brain and the in vivo sensitivity of the blood-brain barrier to disruption by lipopolysaccharide. J Virol 2008; 82:7591-7600.
38. Salaria S, Badkoobehi H, Rockenstein E, et al. Toll-like receptor pathway gene expression is associated with human immunodeficiency virus-associated neurodegeneration. J Neurovirol 2007; 13:496-503. This study linked increased expression of TLRs to HAD.
39. Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res 2008; 6:388-400. Review of potential HIV reservoirs, including the brain.
40. Sadagopal S, Lorey SL, Barnett L, et al. Enhancement of human immunodeficiency virus (HIV)-specific CD8+ T cells in cerebrospinal fluid compared to those in blood among antiretroviral therapy-naive HIV-positive subjects. J Virol 2008; 82:10418-10428.
41. Kipnis J, Derecki NC, Yang C, Scrable H. Immunity and cognition: what do age-related dementia, HIV-dementia and 'chemo-brain' have in common? Trends Immunol 2008; 29:455-463. Interesting review discussing the importance of an intact lymphocytic system for cognition.
42. Wang YJ, Wang X, Zhang H, et al. Expression and regulation of antiviral protein APOBEC3G in human neuronal cells. J Neuroimmunol 2009; 206:14-21.
43. Lindl KA, Akay C, Wang Y, et al. Expression of the endoplasmic reticulum stress response marker, BiP, in the central nervous system of HIV-positive individuals. Neuropathol Appl Neurobiol 2007; 33:658-669.
44. Eletto D, Russo G, Passiatore G, et al. Inhibition of SNAP25 expression by HIV-1 Tat involves the activity of mir-128a. J Cell Physiol 2008; 216:764-770. First study suggesting a role of microRNAs in HIV-induced neuronal injury.
45. Mukerjee R, Deshmane SL, Fan S, et al. Involvement of the p53 and p73 transcription factors in neuroAIDS. Cell Cycle 2008; 7:2682-2690.
46. Norman JP, Perry SW, Reynolds HM, et al. HIV-1 Tat activates neuronal ryanodine receptors with rapid induction of the unfolded protein response and mitochondrial hyperpolarization. PLoS ONE 2008; 3:e3731.
47. Evans SR, Yeh TM, Sacktor N, et al. Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials 2007; 8:437-446.
48. Ances BM, Letendre SL, Alexander T, Ellis RJ. Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders. Int Rev Psychiatry 2008; 20:89-93.
49. Follstaedt SC, Barber SA, Zink MC. Mechanisms of minocycline-induced suppression of simian immunodeficiency virus encephalitis: inhibition of apoptosis signal-regulating kinase 1. J Neurovirol 2008; 14:376-388.
50. Walker DK, Bowers SJ, Mitchell RJ, et al. Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT). Xenobiotica 2008; 38:1330-1339.
51. Kaul M, Lipton SA. Experimental and potential future therapeutic approaches for HIV-1 associated dementia targeting receptors for chemokines, glutamate and erythropoietin. Neurotox Res 2005; 8:167-186.